Christopher Posner

Christopher Posner

DirectoratTvardi Therapeutics· In proxies 2022–2023

Pay in FY2023+16% from the year before · Tvardi Therapeutics stock -93.1% the same year

Christopher Posner was paid $2.9M in FY2023 (Dec), up 16%. Tvardi Therapeutics stock fell 93.1% that year.

Pay$100 in the stock at the end of FY21 → $6
Pay is from the Summary Compensation Table of each Tvardi Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Zevra TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Tvardi TherapeuticsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -100%
  3. KemPharm, Inc.Public company · 1 yr
    • Director2022 – 2023 · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?